| URL | https://www.contractpharma.com/contents/view_break |
| Source | Contract Pharma |
| Date Published | 12/02/2021 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Schott Pharmaceuticals Systems |
| Parent company | Schott |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Capital investment ($): | 60 |
| Country(ies) from which reshored: | Germany |
| City reshored to: | Lebanon |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Nonmetallic Mineral Products |
| Product(s) reshored | specialty glass |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Proximity to customers/market |